When was Exsilio founded?

Exsilio was founded in 2022 and raised its 1st funding round 1 year after it was founded.

Where is Exsilio located?

Exsilio is headquartered in Boston, United States.

Is Exsilio a funded company?

Exsilio is a funded company, having raised a total of $82M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2023.

When was the latest funding round of Exsilio?

Exsilio's latest funding was a $***** Series A round on Apr 08, 2024, with participation from 9 investors. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.16B in funding in 2026 to date.

Where does Exsilio rank among its competitors?

Exsilio ranks 1258th amongst 3787 active competitors, of which 1239 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Exsilio?

Exsilio's top competitors include Jazz Pharmaceuticals, Alnylam and Biogen. Among them, Immuneel secured the most recent funding round in June, 2026.

Exsilio - 2026 Company Profile, Funding & Competitors

Exsilio is a series A company based in Boston (United States), founded in 2022. It operates as a Developer of genomic medicines for a broad range of diseases. Exsilio has raised $82M in funding from investors like Orbimed, Delos Capital and Novartis Venture Fund. The company has 3787 active competitors, including 1239 funded and 886 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Biogen.

Company Details

Developer of genomic medicines for a broad range of diseases. The company is developing genomic medicines that can be delivered in lipid nanoparticles to treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. The company's technology is based on occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates.

Website: exsiliotx.com
Email ID: *****@exsiliotx.com

Key Metrics

Founded Year

2022

Location

Boston, United States

Stage

Series A

Total Funding

$82M in 2 rounds

Latest Funding Round

Series A, Apr 08, 2024, $*****

Investors

Orbimed & 9 more

Ranked

1258^th among 3787 active competitors

Similar Companies

Jazz Pharmaceuticals & 3512 more

View Exsilio's full profile

Exsilio has raised a total funding of $82M over 2 rounds. Its first funding round was on 2023. Its latest funding round was a Series A round on Apr 08, 2024 for $*****. 9 investors participated in its latest round. Exsilio has 10 institutional investors.

Here is the list of recent funding rounds of Exsilio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 08, 2024	5510993	Series A	8856686	2621006	9697279	1761295
2023	3687	Seed	7547	2257	Orbimed	2810

Access funding benchmarks and valuations. Sign up today!

View details of Exsilio's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Exsilio include Jazz Pharmaceuticals, Alnylam and Biogen. Here is the list of Top 10 competitors of Exsilio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 14 others	81/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
5th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	76/100
6th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
7th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
8th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
1258th	Exsilio 2022, Boston (United States), Series A	Developer of genomic medicines for a broad range of diseases	$82M	Invus, Innovation Endeavors & 8 others	39/100